This product has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase. It stops the formation of pain nerve impulses in inflammatory tissues and inhibits inflammatory reactions, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. As for the antipyretic effect, it acts on the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating, which increases heat dissipation. This central antipyretic effect may also be related to the inhibition of prostaglandin synthesis in the hypothalamus.

It acts on dihydrofolate synthase, interferes with the function of folate reductase, and cooperates with trimethoprim to double-block the bacterial folate metabolism. It has antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes and many other bacteria.

It acts on dihydrofolate synthase, interferes with the function of folate reductase, and cooperates with trimethoprim to double-block the bacterial folate metabolism. It has antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes and many other bacteria.

Interfering with the function of synthetic folate reductase, and synergizing with sulfonamides can double block bacterial folate metabolism, thus enhancing antibacterial effects and reducing drug-resistant strains.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor ("P" position), blocking the transfer RNA (t-RNA) from binding to the "P" position, and also blocking the transfer of the polypeptide chain from the acceptor position ("A" position) to the "P" position, thereby inhibiting bacterial protein synthesis.